8-K: ImmunityBio Stockholders Approve New Equity Incentive Plan, Re-elect Directors

ImmunityBio, Inc. announced that its stockholders overwhelmingly approved the 2025 Equity Incentive Plan and re-elected all eight director nominees at its Annual Meeting on June 18, 2025.

Summary

• ImmunityBio, Inc. stockholders approved the 2025 Equity Incentive Plan at the Annual Meeting on June 18, 2025.
• The 2025 Plan replaces the Company's 2015 Equity Incentive Plan, which was scheduled to expire in July 2025; no further awards will be made under the 2015 Plan.
• A total of 46,088,027 new shares of common stock are reserved for issuance under the 2025 Plan, plus up to 32,359,674 shares from expired or forfeited awards under the 2015 Plan, totaling a potential 78,447,701 shares.
• Stockholders re-elected all eight director nominees, including Patrick Soon-Shiong, M.D., Cheryl L. Cohen, Richard Adcock, Michael D. Blaszyk, Wesley Clark, Linda Maxwell, M.D., Christobel Selecky, and Barry J. Simon, M.D., for a one-year term expiring at the 2026 annual meeting.
• Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Approximately 89% of the 882,580,961 outstanding shares (785,427,063 shares) were represented at the Annual Meeting, constituting a quorum.

Sentiment

Score: 7

Explanation: The document reflects positive sentiment as all key proposals, including the new equity incentive plan and director re-elections, were overwhelmingly approved by stockholders, indicating strong support for the company's governance and compensation strategies. The plan's stated purpose is to attract and retain talent, which is a positive for future performance, though potential dilution is a minor consideration.

Positives

• Stockholder approval of the 2025 Equity Incentive Plan is expected to strengthen the Company's ability to attract, retain, and motivate key talent.
• The new plan provides additional incentives for employees, officers, non-employee directors, and other service providers through stock ownership, aiming to improve financial performance and increase profits.
• The overwhelming approval of the equity plan (684,004,688 votes For vs. 18,964,761 Against) and re-election of directors indicates strong stockholder support for the Company's governance and compensation strategy.
• The ratification of Deloitte & Touche LLP ensures continuity in financial auditing and oversight.

Negatives

• The new equity incentive plan reserves a significant number of shares (up to 78,447,701 shares), which could lead to potential dilution for existing shareholders if fully utilized.

Risks

• Shares of Restricted Stock are subject to a 'substantial risk of forfeiture' during their Period of Restriction.
• The Company may deduct or withhold amounts from awards to satisfy 'Tax Withholding Obligations,' and the Company is not responsible for reimbursing or indemnifying participants for taxes imposed by Section 409A or other applicable laws.
• The Administrator has the authority to modify awards without participant consent under certain conditions, including to maintain tax-preferred status, comply with Section 409A, or adhere to other Applicable Laws, which could materially impair participant rights.
• Awards are subject to recoupment under any clawback policy required by listing standards or the Dodd-Frank Act, or other provisions determined by the Administrator, which could lead to forfeiture of previously acquired shares or cash.
• The Company may terminate or cancel awards with or without consideration if it determines it is impossible or impractical to comply with regulatory requirements or obtain necessary approvals for share issuance.
• If a participant fails to accept an award or take necessary administrative steps, the award may be cancelled, and shares revert to the plan for no additional consideration.

Future Outlook

The approval of the 2025 Equity Incentive Plan is intended to strengthen the Company's ability to attract, retain, and motivate key talent, providing additional incentives through stock ownership to improve financial performance and increase profits in the long term.

Management Comments

• "The Board believed it to be in the long-term interest of both the Company and its stockholders to strengthen the Company’s ability to attract, retain and motivate employees, officers, non-employee directors and certain other service providers and to provide additional incentive for those persons through stock ownership and other incentives to improve financial performance, increase profits and strengthen the mutuality of interest between those persons and the Company’s stockholders."

Industry Context

The adoption of a new equity incentive plan is a standard corporate governance practice for publicly traded companies, particularly in competitive sectors like biotechnology or pharmaceuticals, to ensure they can attract and retain top talent. The size of the share reserve reflects the company's strategy to use equity as a key component of its compensation structure, aligning employee incentives with shareholder value creation, a common trend across growth-oriented industries.

Comparison to Industry Standards

• The aggregate value limit for Outside Director compensation ($750,000 annually, $1,000,000 in the initial year) is within the typical range for publicly traded companies of similar market capitalization and industry, aiming to balance competitive compensation with shareholder interests.
• While specific comparable companies are not mentioned in the filing, such limits are generally benchmarked against peer groups in the biotechnology and pharmaceutical sectors to ensure competitive director remuneration without excessive dilution.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution due to the significant number of shares reserved for the 2025 Equity Incentive Plan. However, the plan aims to align management and employee interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees, Officers, Non-employee Directors, and Service Providers: Direct positive impact through the availability of new equity-based awards (Options, SARs, Restricted Stock, RSUs, Performance Awards), enhancing compensation and incentivizing performance and retention.

Next Steps

• The 2025 Equity Incentive Plan is now effective, allowing the Company to grant new equity-based awards.
• The re-elected directors will serve for a one-year term expiring at the 2026 annual meeting of stockholders.
• Deloitte & Touche LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

ImmunityBio, IBRX, Equity Incentive Plan, Stockholder Meeting, Corporate Governance, Stock Options, Restricted Stock, Performance Awards, Executive Compensation, SEC Filing, 8-K, Biotechnology, Pharmaceuticals